ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
The Impact of a Carbapenem-Resistant Enterobacteriaceae Outbreak on Facilitating Development of a National Infrastructure for Infection Control in Israel.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Temporal trends and patterns in neonatal sepsis mortality across 194 countries, 2000-2021, with projections up to 2050.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Prevalence, multidrug resistance patterns, and carbapenemase-encoding genes of carbapenemase-producingSAGE open medicine · 2026Review
- [Review of International Literature for the Prevention and Control of Carbapenem-resistantJugan geon-gang gwa jilbyeong · 2024Review
- Reflections on a national public health emergency response to carbapenemase-producing EnterobacteraleEpidemiology and infection · 2022Article
- Validation and Extrapolation of a Multimodal Infection Prevention and Control Intervention on Carbapenem-ResistantFrontiers in medicine · 2021Article
- Epidemiology of β-Lactamase-Producing Pathogens.Clinical microbiology reviews · 2020Review
- Antimicrobial use trends, Israel, 2012 to 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Observational
- What are the main drivers for public policies to prevent healthcare-associated infections?The Journal of hospital infection · 2019Article
- Trends in antimicrobial resistance in Israel, 2014-2017.Antimicrobial resistance and infection control · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2006 the Israeli healthcare system faced an unprecedented outbreak of carbapenem-resistant Enterobacteriaceae, primarily involving KPC-producing Klebsiella pneumoniae clonal complex CC258. This public health crisis exposed major gaps in infection control. In response, Israel established a national infection control infrastructure. The steps taken to build this infrastructure and benefits realized from its creation are described here.
Indexed as
Identifiers
29020228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.